Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 10/20 | 0.33 |
| ▸ | AURKA | O14965 | 8/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967077 | 1.00 | RPS6KB1 (0.33) | RPS6KB1AURKAMETAP1METAP2MAP4K1 | |
| SCHEMBL15238261 | 0.90 | STK17B (0.40) | RPS6KB1AURKA | |
| SCHEMBL2723226 | 0.90 | STK17B (0.40) | RPS6KB1AURKA | |
| SCHEMBL20584282 | 0.90 | STK17B (0.40) | RPS6KB1AURKA | |
| SCHEMBL21967074 | 0.83 | STK17B (0.33) | — | |
| SCHEMBL17595889 | 0.82 | STK17B (0.31) | — | |
| SCHEMBL21967068 | 0.82 | — | — | |
| SCHEMBL21967069 | 0.82 | — | — | |
| SCHEMBL23868090 | 0.82 | NR3C1 (0.31) | — | |
| SCHEMBL2725643 | 0.79 | STK17B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | RPS6KB1 486/4885AURKA 64/4885METAP1 4241/4885 |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | RPS6KB1 622/4885AURKA 345/4885METAP1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.